Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer von Denys, Hannelore, Martinez-Mena, CL, Martens, MT, D'Hondt, RG, Graas, ML, Evron, E, Fried, G, Ben-Baruch, NE, Vulsteke, C, Van Steenberghe, MM

Volltext

Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B von Vivian, Julian P., Duncan, Renee C., Berry, Richard, O’Connor, Geraldine M., Reid, Hugh H., Beddoe, Travis, Gras, Stephanie, Saunders, Philippa M., Olshina, Maya A., Widjaja, Jacqueline M. L., Harpur, Christopher M., Lin, Jie, Maloveste, Sebastien M., Price, David A., Lafont, Bernard A. P., McVicar, Daniel W., Clements, Craig S., Brooks, Andrew G., Rossjohn, Jamie

Volltext